Please login to the form below

Not currently logged in
Email:
Password:

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Gilead strikes deal with NHS England on CAR-T Yescarta

Today’s agreement will see around 200 adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma be eligible for treatment. ... CAR-T cell therapy is one of the most promising new treatments in a generation for

Latest news

More from news
Approximately 1 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's Tyrosine Kinase.

  • Pharma deals in April 2015 Pharma deals in April 2015

    MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT: Technology transfer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Celgene partnered with Bluebird on a portfolio of CAR-T candidates in 2013, and followed that up with a deal to zero in on B-cell maturation antigen (BCMA) two years ... That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics